Psoriatic Arthritis

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 29, 2022.

Randomized clinical trials evaluating the effect of bDMARD or tsDMARD treatment in patients with psoriatic arthritis were included in the analysis.

Low disease activity may be the most appropriate treatment target for patients with high levels of structural damage and functional disability.

Risankizumab showed linear and time-independent pharmacokinetics in patients with active psoriatic arthritis and was comparable to those with plaque psoriasis.

Dr. Veronica Anwuri discusses how apremilast (Otezla), the first oral, non biologic treatment option for plaque psoriasis can address the systemic pain associated with psoriatic arthritis.

A long-term, post-authorization safety study of adverse events was performed for patients with PsO and/or PsA exposed to apremilast.

Although the proportion of women treated with biologics continues to grow, data on treatment recommendations among both physicians and female patients of childbearing age remain limited.

“This class of medication provides an alternative therapeutic option for those that have an inadequate response to conventional DMARDs or biologic therapy.”

Terence Rooney, MD, discusses the ongoing STAR study in depth and the potential of guselkumab to improve axial psoriatic arthritis.

"Dactylitis is considered a core domain of musculoskeletal symptoms in psoriatic arthritis and is important for both patients and physicians when developing treatment strategies.”

CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, frequently co-occurs with the immune-mediated inflammatory condition, psoriasis.

In this Q&A, Tamara van Hal, MD, discussed the findings of her study that evaluated the extent of work and activity impairment in patients with psoriatic arthritis and examined determinants associated with this impairment.

In the prospective, non-interventional SUSTAIN study, patients with active psoriatic arthritis received ustekinumab for 3 years in routine clinical care.

"Sex may play an underlying role in driving the mechanisms of psoriatic arthritis, leading to different clinical manifestations of the disease," investigators theorized.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 27, 2022.

"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”

Rheumatology Network interviewed Paul M. Peloso, MD, MSc, Chief Medical Officer at Acelyrin, to discuss recent phase 2 data examining the safety and efficacy of izokibep in the treatment of psoriatic arthritis.

The US Food and Drug Administration approved of the citrate-free, high-concntration (100 mg/mL) formulation of adalimumab-bwwd, a biosimilar of adalimumab, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis.

“Given the complex nature of PsA, patients should also be involved in defining their treatment goals, as every patient may have different perspectives on the target for therapy and the means to achieve it.”

Although the current treatment strategies for children with juvenile idiopathic arthritis help to relieve pain symptoms, these medications provide limited efficacy on the underlying disease.

Serum calprotectin level may be a useful biomarker associated with a high inflammatory burden and the presence of carotid plaque.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 13, 2022.

Patients with psoriatic arthritis receiving risankizumab reported improved joint and skin symptoms when compared with placebo.